Reframing Alzheimer's Disease Through a Redox-Metabolic Framework. (PubMed, Int J Mol Sci) - Sep 27, 2026 - "Evidence for lecanemab and donanemab supports an integrative rather than replacement model of AD treatment. This framework may facilitate earlier diagnosis, patient stratification, and complementary disease-modifying interventions."
Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Metabolic Disorders • Proteinopathy
|
|
Amador Velázquez de Castro-Bono; Gracia Castro-Luna; José Luis Guil-Guerrero
|